Home | Welcome to Contract Pharma   
Last Updated Saturday, August 23 2014
Print

Topics - Cytotoxics and High Potency Manufacturing


Refine by Date:
From: To:
Published July 16, 2014
Upgrades cytotoxic capabilities at Glasgow Read More »
Published June 2, 2014
Expands commercial manufacturing capabilities for specialty injectables Read More »
Published May 28, 2014
Adds HPAPI processing capabilities at Shanghai lab Read More »
Published May 15, 2014
New HPAPI capacity at Le Mans facility boosts capabilities for anti-cancer therapies 
 Read More »
By Kristin Brooks
Published February 27, 2014
Landais to head Asia-Pacific region Read More »
By Kristin Brooks
Published January 27, 2014
Demonstrates proficiency in the safe handling of potent APIs and compounds Read More »
By Gil Roth
Published January 10, 2014
ADC increased overall survival in Ib trial Read More »
Formex Makes Its AAPS Debut
By Gil Roth
Published December 3, 2013
Rudy Emmelot on Formex' first AAPS show Read More »
Safebridge Talks Safety
By Gil Roth
Published December 3, 2013
John P. Farris of SafeBridge at AAPS 2013 Read More »
By Gil Roth
Published December 2, 2013
AcelRx, Ampio, Biogen Idec, Exelixis, Idenix, Polaris Read More »
By Gil Roth
Published November 18, 2013
Raiche to lead process, product development teams Read More »
By Gil Roth
Published November 18, 2013
Exceeds expectations with new containment facility Read More »
By Gil Roth
Published November 15, 2013
Amakem, Bayer, GW, OncoMed, Opko Read More »
By Gil Roth
Published November 15, 2013
Radio-treatment approved in U.S. in May 2013 Read More »
High Potency Regulations
By Stephanie Wilkins, PharmaConsult US, Inc.
Published November 13, 2013
Uncertainty remains in the quest to define certain products Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On